Organization (Industry)
CSL LIMITED
ClinicalTrials.gov lists CSL LIMITED as lead sponsor of 155 trials, counting the companies grouped under it. CSL LIMITED itself has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers CSL LIMITED and 4 companies grouped under it: 155 lead-sponsored trials (10 its own, 145 in the grouped companies) and 18 legal-entity registrations (9 its own, 9 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| CSL Behring GmbH | 145 | 6 |
| CSL Behring Lengnau AG | 0 | 1 |
| CSL Plasma GmbH | 0 | 1 |
| VIFOR PHARMA BELGIE | 0 | 1 |
Disease areas (7)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Primary Immunodeficiency Diseases | 3 |
| Leukemia, Myeloid, Acute | 2 |
| Acute Coronary Syndrome | 1 |
| Asthma | 1 |
| Hemorrhage | 1 |
Showing 5 of 7 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2012 | 3 |
| 2011 | 1 |
| 2010 | 1 |
| 2008 | 1 |
| 2007 | 3 |
| 2006 | 1 |
| 2005 | 1 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Immune Globulin | 1 |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| British journal of clinical pharmacology | 1 |
| Internal medicine journal | 1 |
| JAMA | 1 |
| Journal of clinical immunology | 1 |
| Journal of clinical pharmacology | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 144 | 17 | 2025-11-11 |
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| CSL Behring (Colombia) | Parent of | 11 |
| CSL Behring (Colombia) | Ultimate parent of | 11 |
| Parexel | Co sponsors trial with | 1 |
| Parexel | Uses vendor | 1 |
Latest dated events (155)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-01 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-08-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-04-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 155 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial exclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| ALB | Trial sponsor | Mentioned in trial text |
| ALB | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.